Latest News
Spinifex Pharmaceuticals, an Australian pain drug development company, has secured a further AUD6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.
This expanded Series B funding builds on a previously announced AUD12 million investment from the same syndicate and will be used in part to expand the Phase 2 clinical trial program for EMA401 to a further two indications, specifically; the treatment of pain and hypersensitivity in peripheral nerve injury patients; and the treatment of pain
KalVista Pharmaceuticals (KalVista), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
The company is developing novel, small molecule plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries and a major unmet medical need. KalVista’s advanced pre-clinical product pipeline is targeting both intravitreal injection and oral administration routes. KalVista acquired these inhibitors plus all relevant intellectual property from Vantia Therapeutics.
KalVista’s scientific founders
Ogier Fiduciary Services Cayman Limited (OFSCL) has announced a new management structure designed to allow its leadership team to focus and develop capabilities for specific lines of business and build even deeper partnerships with clients.
“The growth and diversification of the fiduciary services business and Ogier Cayman overall has required us to look at our operating philosophy and structure in terms of current and prospective client needs,” says Colin MacKay, Group Director, Ogier Fiduciary Services. “The changes we’re announcing today reflect client demand for specialised capabilities across our lines of business and put us in an excellent position to capitalise
Chinese buyers have continued to show their strength in 2011 despite ongoing global economic uncertainty, according to a new report from Robert W Baird & Co, a global investment bank with extensive experience in middle market, cross-border M&A and offices in Shanghai and Hong Kong.
Baird’s latest twice-yearly China M&A Market report shows that outbound M&A rose strongly in the first half of this year, with the number of majority-interest deals up more than 40% on the same period in 2010. In value terms, the rise was 50%. The story for inbound M&A was in stark contrast, as the deal
Global private equity firm Vector Capital has completed its USD283, acquisition of Gerber Scientific, Inc, an international supplier of sophisticated automated manufacturing systems for the sign making, specialty graphics, packaging, apparel and industrial industries.
CITIC Capital Partners, a China based private equity firm, will take a minority stake in Gerber Scientific alongside Vector.
Gerber Scientific’s stockholders approved the take-private transaction at a special meeting of the stockholders on 18 August, 2011. Under the terms of the merger agreement, Gerber Scientific stockholders will receive USD11.00 per share in cash, plus a non-transferable contractual right to receive additional contingent cash consideration payments
Fund administrator HedgeServ has expanded its international platform with the opening of an office in London on 22 August.
The office, located at 21 Upper Brook Street, W1, will focus on business development with hedge funds, funds of hedge funds, private equity funds, and institutional investment managers.
"Our entry into London reflects our commitment to answering the global demand for HedgeServ’s innovative, high-quality fund administration services," says Justin Nadler, president of HedgeServ. "We are well-positioned to deliver local expertise to clients through our growing London presence and our established Dublin office, with 250 experienced fund accounting, middle-office operations, and investor
OSK International Investments Hong Kong Ltd, a subsidiary of OSK Holdings Berhad, one of Malaysia’s leading investment services firms, is to launch a new resource investment fund as part of a broad ranging initiative to boost the company’s presence in Hong Kong.
The new fund, the OSK Resources Fund, will invest in companies directly involved in the natural resources sector, especially those focused on China’s rapidly expanding appetite for hard and soft commodities. Other funds covering other sectors including Islamic funds are expected to follow.
HealthPlan Holdings, a portfolio company of Water Street Healthcare Partners, has acquired Zenith Administrators, Inc. The company will merge Zenith with its subsidiary, American Benefit Plan Administrators, Inc, creating a national third-party administrator of health care, retirement and other benefits to Taft-Hartley trust funds, and state and municipal plans.
Together, ABPA and Zenith will have more than 1,200 employees dedicated to providing benefit administration services to nearly 2 million plan participants across the country. The newly merged companies will offer customers the broadest range of services to administer benefits and manage compliance requirements associated with their Taft-Hartley plans. In addition,
Capital IQ has launched its first iPad application for the Capital IQ platform. The application offers clients the ability to sync documents such as investment research, investor meeting transcripts and company filings to their iPad for easy offline access.
Mobile access to the Capital IQ platform itself, including the majority of its unique workflow tools, is already available via Apple’s Safari and other browsers.
"We are excited to provide our users with a mobile solution that fits how they work on-the-go," says Colleen Coda, Chief Technology Officer at Capital IQ. "Our iPad app provides fast, easy access to the documents
The board of Castle Private Equity AG , the SIX Swiss Exchange listed fund of private equity funds, proposed on 13 July 2011 to buy back own shares for cancellation up to a maximum value of USD 15 million.
Regulatory approval has now been received for the buyback of up to 4% of the share capital, equivalent to a maximum of 1,728,000 shares. The effective size of the programme remains at the discretion of the board to account for portfolio liquidity and market conditions.
To ensure tax efficiency the share buyback programme will be executed via a second trading line denominated in CHF,
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
